Vulvar Metastasis from Bladder Cancer

Fouad Aoun, 1 Elie El Rassy, 2 Hampig Raphael Kourie, 2 Eric Hawaux, 1 and Roland van Velthoven 1

1Department of Urology, Jules Bordet Institute, Free University of Brussels (ULB), 1 Héger Bordet Street, 1000 Brussels, Belgium
2Department of Oncology, Jules Bordet Institute, Free University of Brussels (ULB), 1 Héger Bordet Street, Brussels, Belgium

Correspondence should be addressed to Fouad Aoun; fouad.aoun@bordet.be

Received 27 February 2015; Revised 13 April 2015; Accepted 16 April 2015

Academic Editor: Kaei Nasu

Copyright © 2015 Fouad Aoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vulvar metastasis of urothelial carcinoma of the bladder is a very rare entity; few cases are reported in the English literature. In this paper, we describe the clinical and pathological characteristics, evolution, and treatment of a patient with vulvar metastasis of urothelial carcinoma of the bladder followed by a brief review of the reported cases in the literature.

1. Introduction

Cancer of the vulva, primary or metastatic, is a very rare tumor constituting <1% of all female cancers. Particularly, primary vulvar cancers are responsible for 3–5% of gynecologic tumors whilst metastatic vulvar cancers are less common constituting 5–8% of vulvar cancers [1]. Metastases from bladder cancer most frequently involve the lymph nodes, bones, lung, liver, and peritoneum. Metastatic tumors sparing these five sites occur in 3% of the cases and affect the pleura, soft tissue, adrenal glands, or brain [2]. Metastasis to the female reproductive tract is rare. When it does occur, the genitourinary tract is the next most frequently reported primary origin [3]. Here, we report a vulvar metastasis of urothelial bladder carcinoma and describe its clinical and pathological features.

2. Case History

A 63-year-old multigravida, alcoholic, and heavy smoker female patient presented to our department late 2011 for stage IV small cell lung cancer. The diagnosis was established following surgical resection of a symptomatic metastatic cerebellar mass herniation. The patient received total brain radiotherapy and six cycles of Cisplatin-VP16 chemotherapy and was advised close follow-up.

The patient presented back in November 2012 with an abrupt onset of urinary incontinence. Investigations revealed stable lung disease and right side uretrohydronephrosis attributed to a bladder tumor. Transurethral resection of the tumor revealed a completely necrotic mass determined as urothelial carcinoma staged G3pT2. Consequently, we performed anterior pelvectomy that demonstrated a transitional cell carcinoma staged pT3bN0M0 and considered adjuvant treatment that the patient strictly refused.

On follow-up six months later, the patient was cachectic with a performance status of 4. Clinical exam revealed vaginal secretions, solid and tender right inguinal lymph nodes, and tumefaction of the right greater vulvae. Her thoracic and brain lesions were stable but retroperitoneal magnetic resonance imaging showed a fluid collection limited to the greater vulvae. Her blood tests showed an inflammatory pattern with increased C-reactive protein 89 g/L and white blood cells at 12620/μL with neutrophils 82%. Fluid cultures of the vulvar tumefaction grew Escherichia coli and Proteus mirabilis but the tumefaction failed to resolve after appropriate antibiotic therapy. Unfortunately, excisional biopsy of the mass showed metastasis of a high grade urothelial carcinoma.

3. Discussion

The entire female genital tract is at risk for metastases occurrence from intragenital and extragenital primaries most commonly gastrointestinal adenocarcinomas [4]. The vulva is the least metastatic site of the female genital tract with the labia majora being the most common location [5]. It
Table 1: Review of the literature-clinopathological features of metastatic urothelial carcinoma to the vulva.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Number</th>
<th>Age (years)</th>
<th>Symptoms</th>
<th>Primary</th>
<th>Interval</th>
<th>Sites of metastasis</th>
<th>Tissue involvement</th>
<th>Other metastases</th>
<th>Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dehner (1973) [3]</td>
<td>2</td>
<td>48</td>
<td>Hematuria and dysuria</td>
<td>Urothelial urethra</td>
<td>Synchronous</td>
<td>Labia majora</td>
<td>NR</td>
<td>No</td>
<td>Vulvovaginectomy with bilateral inguinal lymphadenopathy</td>
<td>Living well at 130 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Urothelial urethra</td>
<td>19 months</td>
<td>Perineum</td>
<td>NR</td>
<td>No</td>
<td>Pelvic exenteration</td>
<td>Died of disease at 58 months</td>
</tr>
<tr>
<td>Cohen et al. (1988) [9]</td>
<td>1</td>
<td>NR</td>
<td>Painless nodule</td>
<td>Kidney</td>
<td>&gt;8 months</td>
<td>Vulvae</td>
<td>NR</td>
<td>No</td>
<td>SR</td>
<td></td>
</tr>
<tr>
<td>Lerner et al. (1999) [5]</td>
<td>1</td>
<td>78</td>
<td>Painful nodule</td>
<td>Urothelial bladder</td>
<td>Synchronous</td>
<td>Vulvae</td>
<td>NR</td>
<td>No</td>
<td>SR</td>
<td></td>
</tr>
<tr>
<td>Boardman et al. (2001) [10]</td>
<td>2</td>
<td>71</td>
<td>Pagetoid vulvae</td>
<td>Urothelial CIS bladder</td>
<td>12 months</td>
<td>Vulvae</td>
<td>NR</td>
<td>Yes</td>
<td>Radical vulvectomy</td>
<td>Died of disease at 65 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64</td>
<td>Pagetoid vulvae</td>
<td>Urothelial CIS bladder</td>
<td>Synchronous</td>
<td>Vulvae</td>
<td>NR</td>
<td>Yes</td>
<td>Radical vulvectomy + chemotherapy</td>
<td>Follow-up at 8 months: no disease</td>
</tr>
<tr>
<td>Neto et al. (2003) [6]</td>
<td>2</td>
<td>54</td>
<td>Cyst</td>
<td>Bladder</td>
<td>2 months</td>
<td>Labia majora</td>
<td>ep + der + subc</td>
<td>Yes</td>
<td>Xrt</td>
<td>Died of disease at 2 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>53</td>
<td>Mass</td>
<td>Urethra</td>
<td>12 months</td>
<td>Labia majora</td>
<td>ep + der + subc</td>
<td>Yes</td>
<td>Xrt</td>
<td>Died of disease at 12 months</td>
</tr>
<tr>
<td>Our case (2015)</td>
<td>1</td>
<td>63</td>
<td>Painless nodule</td>
<td>Bladder</td>
<td>12 months</td>
<td>Vulvae</td>
<td>NR</td>
<td>Yes</td>
<td>Xrt</td>
<td></td>
</tr>
</tbody>
</table>

der: dermis; ep: epidermis; mo: month; NR: not reported, Sepi: squamous epithelium; Subc: subcutis; Xrt: radiotherapy.

is noteworthy to mention that the occurrence of vulvar metastasis represents an end stage disease as it underlines, in general, a widespread incurable disease [6].

The metastatic patterns of urothelial carcinoma of the bladder are not fully elucidated. Limited data underlines a variable metastatic potential that allows this carcinoma to involve any organ by affecting certain genes and proteins, including p53, E-cadherin, Bcl-2, and insulin-like growth factor binding protein 2 gene [2]. Metastasis occurred commonly in more than one organ with 20–45% of patients having at least one metastasis [2, 7]. Possible mechanisms for distant metastasis include vascular or lymphatic spread, seeding, and iatrogenicity. Local recurrence is explained by seeding and multicentricity [8]. In the particular case of metastatic spread of the malignant cells to the vulva, it appears that vulvar metastatic disease is associated with vascular involvement of the vulvar tissue [9]. One paper attributed vulvar metastases to vascular space involvement with the exception of primary transitional cell carcinomas [3]. One patient presented with hematuria, dysuria, and incidental labial nodule on physical exam. She received vulvovaginectomy with bilateral inguinal lymphadenopathy and died 130 months later without evidence of disease. The other presented a mobile, painless perineal nodule 19 months after diagnosis of transitional cell carcinoma that received pelvic exenteration and died 39 months after recurrence with local and pulmonary metastasis. In one paper, Boardman et al. report two cases of metastatic bladder transitional cell carcinoma to the vulvae. One case presented at diagnosis a synchronous metastatic disease with a pagetoid manifestation. She received radical vulvectomy and systemic chemotherapy and was in complete remission at 8 months. The second case had the same manifestation one year after her initial diagnosis. She was treated with radical vulvectomy and died of disease 65 months later. An interesting series by MD Anderson Cancer Center reports 66 cases of metastatic tumors to the vulva. The mean age at diagnosis was 54.8 years (range: 18 to 84 years) [7]. Most commonly, patients presented with vulvar mass 59%, pain 11%, and ulceration 8%. Whilst only 9% had unknown primary tumor, it was of urothelial origin in 3% of cases and nonurothelial origin in the remainder. In this series, two patients presented with urothelial tumors manifesting by a mass or a cyst. Both
patients received radiotherapy and died of disease at 2 and 12 months for the bladder and urethral disease successively.

The core tip of this case is to maintain a high index of suspicion for vulvar metastasis in women with extremely unusual vulvar swellings and a past history of cancer. Early detection and appropriate treatment of these unusual sites could highly affect the prognosis of these patients.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References


